FDA takes heat from Congress for heparin scare
Letters criticizing FDA following a heparin safety scare to FDA Commissioner Andrew von Eschenbach and HHS Secretary Michael Leavitt claim the agency has "deliberately failed to apply" its pre-approval "inspection policy to drug manufacturers in China." The Feb. 21 letters, from House Energy and Commerce Committee Chairman John Dingell, D-Mich., and Subcommittee on Oversight and Investigations Chairman Bart Stupak, D-Mich., follow a Feb. 19 announcement from an FDA compliance official that the agency inspected the wrong heparin active pharmaceutical ingredient manufacturer, a fumble that may be related to a recent safety scare including four deaths associated with Baxter heparin products. The congressmen are considering legislation requiring FDA to inspect a firm before it ships product to the U.S...
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.